Effects of fluvastatin on plasma lipid abnormalities in hemodialysis patients with chronic renal failure

Japanese Journal of Nephrology

Volumn 44, Issue 4, 2002, Pages 402-408

  Tanaka, Motoko ^a   Itoh, Kazuko ^b   Matsushita, Kazutaka ^b   Kitamura, Kenichirou ^a   Nonoguchi, Hiroshi ^b   Tomita, Kimio ^b  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b School of Medicine ^*

Author keywords

Atherogenesis; Hemodialysis; HMG CoA reductase inhibitor; Lipid metabolism; Oxidative stress

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OXIDATIVE PHOSPHORYLATION; STATISTICAL SIGNIFICANCE;

AGED; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 0036308944     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Steinberg D, Lewis A. Conner memorial lecture - oxidative modification of LDL and atherogenesis -. Circulation 1997 ; 95 : 1062.
2. Berliner JA, Navab M, Fogelman AM. Atherosclerosis : Basic mechanism, oxidation, inflammation and genetics. Circulation 1995 ; 91 : 2488-96.
3. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001 ; 37 : 750-7.
4. Kuroda M, Asaka S, Tofuku Y, Takeda R. Serum antioxidant activity in uremic patients. Nephron 1985 ; 41 : 293-8.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JG, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989 ; 320(14) : 915-24.
6. Gonen B, Goldberg AP, Harter HR, Schonfeld G. Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure. Metabolism 1985 ; 34 : 10-4.
7. Yukawa S, Hibino A, Maeda T, Mimura K, Yukawa A, Maeda A, Kishino M, Sonobe M, Mune M, Yamada Y, Nishide I. Effect of α-tocopherol on in vitro and in vivo metabolism of low density-lipoproteins in haemodialysis patients. Nephrol Dial Transplant 1995 ; 10 (Suppl 3) : 1-3.
8. Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, Takahashi T, Kodama N, Saika Y, Yamada Y. Effects of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int 1999 ; 56 (Suppl 7) : 126-9.
9. Boaz M et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) : randomized placebo-controlled trial. Lancet 2000 ; 356 : 1213-8.
10. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int 1999 ; 56 (Suppl 71) : 134-6.
11. Antosiewicz J, Damiani E, Jassem W, Wozniak M, Orena M, Greci L. Influence of structure on the antioxidant activity of indolinic nitroxide radicals. Free Radical Biol & Med 1997 ; 22 : 249-55.
12. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997 ; 128 : 11-8.
13. Suzumura K, Tanaka K, Yasuhara M, Narita H. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein. Biol Pharm Bull 2000 ; 23 (7) : 873-8.
14. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology & Therapeutics 1999 ; 84 : 413-28.
15. Wanner C, Hörl WH, Luley CH, Wieland H. Effects of HMG-CoA reductase inhibitors in hypercholesteroraic patients on hemodialysis. Kidney Int 1991 ; 39 : 754-60.
16. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997 ; 131 : 229-36.
17. Appel S, Dingemanse J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs of Today 1996 ; 32 : 39-55.